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ABSTRACT
Handgrip Strength in Children with Cystic Fibrosis
Hannah Taylor Gibson
Department of Nutrition, Dietetics & Food Science, BYU
Master of Science
Background: Body mass index (BMI) is the primary accepted method to determine nutrition
status in children with cystic fibrosis (CF); however, lean body mass (LBM) is more strongly
associated with pulmonary function. Handgrip strength (HGS) measures muscle function and is
reflective of LBM. The aims of this study were to assess if there was a relationship among HGS,
nutrition status, and pulmonary function, to assess if HGS changed after hospitalization, and to
assess if there was a relationship between HGS and nutrient intake. Methods: Twenty-three
children with CF ages 6-18 years participated. BMI z-scores, nutrition risk scores, and
pulmonary function were assessed about five months before, day 5-7 of, and about six weeks
after hospitalization. HGS z-scores and arm anthropometrics were measured during and after
hospitalization. Nutrient intakes were assessed during hospitalization. Results: Mean dominant
HGS z-score was -1.95 ± 0.92 at hospitalization and -1.59 ± 1.06 at follow-up (p=0.007). Mean
BMI z-score was -0.09 ± 0.64 at hospitalization and 0.06 ± 0.54 at follow-up (p=0.178). No
significant relationship was found between HGS z-scores and BMI z-scores (p=0.892) or HGS zscores and pulmonary function (p=0.340). Conclusions: HGS z-scores were lower than the
standard even though mean BMI z-scores classified participants as normal nutrition status.
Further research should be done utilizing a larger sample size in order to better examine HGS’s
potential as a nutrition assessment tool in this population.
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MANUSCRIPT
Prepared for the Journal of Pediatric Gastroenterology and Nutrition
ABSTRACT
Background: Body mass index (BMI) is the primary accepted method to determine nutrition
status in children with cystic fibrosis (CF); however, lean body mass (LBM) is more strongly
associated with pulmonary function. Handgrip strength (HGS) measures muscle function and is
reflective of LBM. The aims of this study were to assess if there was a relationship among HGS,
nutrition status, and pulmonary function, to assess if HGS changed after hospitalization, and to
assess if there was a relationship between HGS and nutrient intake. Methods: Twenty-three
children with CF ages 6-18 years participated. BMI z-scores, nutrition risk scores, and
pulmonary function were assessed about five months before, day 5-7 of, and about six weeks
after hospitalization. HGS z-scores and arm anthropometrics were measured during and after
hospitalization. Nutrient intakes were assessed during hospitalization. Results: Mean dominant
HGS z-score was -1.95 ± 0.92 at hospitalization and -1.59 ± 1.06 at follow-up (p=0.007). Mean
BMI z-score was -0.09 ± 0.64 at hospitalization and 0.06 ± 0.54 at follow-up (p=0.178). No
significant relationship was found between HGS z-scores and BMI z-scores (p=0.892) or HGS zscores and pulmonary function (p=0.340). Conclusions: HGS z-scores were lower than the
standard even though mean BMI z-scores classified participants as normal nutrition status.
Further research should be done utilizing a larger sample size in order to better examine HGS’s
potential as a nutrition assessment tool in this population.
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INTRODUCTION
Cystic Fibrosis (CF) is a life-threatening genetic disorder that can lead to significant lung
damage, malnutrition, and other complications. Nutrition plays a critical role in the overall health
status of individuals with CF.1, 2 There is a longitudinal relationship between nutrition status,
growth, pulmonary function, and survival.2, 3, 4 Identifying individuals at risk for undernutrition
as timely as possible is necessary for prevention and early intervention of nutritional failure.
Strong evidence suggests that early interventions, such as increasing energy intake, result in
improved weight gain and nutrition status in children with CF.2 Adequately monitoring nutrition
status and growth is critical to maintain and improve pulmonary function.
Nutrition status in children with CF is monitored by a variety of methods including:
anthropometric measurements, nutrition risk score, and nutrient intake.5 Body mass index (BMI)
is the primary accepted method to determine nutrition status in children with CF.6, 7 The CF
Foundation Nutrition Guidelines recommend children between the ages of 2-19 years maintain a
BMI above the 50th percentile or a BMI z-score above zero.6 BMI is a measure of weight
adjusted for height (kg/m2) and does not distinguish between lean body mass (LBM) and fat
mass. Nutrition risk score is a risk-based classification system used to determine individuals who
may benefit from more extensive medical nutrition therapy.5
Nutrient intake addresses how many calories a child is consuming and if that child is
meeting their recommended energy and protein needs. Children with CF require about 1.5 to 2
times more energy than those without CF to breathe normally, fight infection, and compensate
for poor digestion. 2, 8 Traditionally, nutrition interventions focused on increasing fat intake in
order to increase energy consumption, but there is concern that this approach is not promoting
LBM.2
2

Stronger associations have been found between LBM and pulmonary function than BMI
and pulmonary function in CF patients.9, 10 Decreases in LBM are associated with decreases in
pulmonary function; however, LBM is not being assessed routinely and BMI is used to gauge
nutrition status in clinical settings.6
There are several methods used to examine LBM. Dual-energy X-ray absorptiometry
(DXA) scans are one of the most accurate ways to measure LBM and are commonly used in
research; however, they are expensive and impractical for everyday use in a clinic. Bioelectrical
impedance is another method to assess LBM but has been found to be inaccurate in persons with
CF due to an imbalance in electrolytes.11, 12 Arm anthropometry measurements including triceps
skinfolds (TSF), mid-upper arm circumference (MUAC), and arm muscle area (AMA) have been
reviewed as possible methods to assess LBM, yet these methods have led to inconsistent results
in the CF population.12, 13 It has been concluded that neither skinfold measurements nor
bioelectrical impedance should be included in the standard nutrition assessment of CF patients.14
The Jamar® Plus Hand Dynamometer is a validated tool used to measure handgrip
strength (HGS), is suitable for a clinical setting, and has been used to measure muscle function in
a variety of populations, including adults with CF.15, 16, 17 The Jamar® Plus Hand Dynamometer
has established reliability based on test-retest reproducibility and excellent inter-rater
reliability.18 Muscle function determined by HGS is reflective of LBM and responds earlier to
changes in nutritional status than muscle mass.19, 20 Significant positive associations were found
between HGS, LBM, and pulmonary function in adults with CF.17 To our knowledge,
associations among HGS, nutrition status, and pulmonary function have not been studied in
children with CF nor have changes in HGS overtime in children with CF been examined. Earlier
detection of reductions in LBM would allow for earlier interventions, and likely prevent further
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deterioration of pulmonary function. HGS may be a more sensitive way to measure changes in
LBM in children with CF and may be a valuable measurement to assess nutrition status in
children with CF.
The primary purposes of this study were to assess if there was a relationship among HGS
z-scores, nutrition status (BMI z-scores, nutrition risk scores, and AMA z-scores), and
pulmonary function (FEV1) in children ages 6-18 years with CF and to assess if HGS z-scores
changed between hospitalization and after hospitalization at an outpatient CF clinic follow-up
appointment. The secondary purpose was to assess if there was a relationship between HGS zscores and nutrient intake, specifically energy and protein intake.

METHODS
Study Setting and Design
A convenience sample of 23 children, ages 6-18 years, with CF participated in a
longitudinal study from August 2016 to April 2017. Eligible participants were admitted to 289bed pediatric specialty hospital within three days of their outpatient CF clinic appointment, able
to read and understand verbal directions in English, and able to perform the HGS measurement.
Children positive for Burkholderia cepacia were excluded. The researcher obtained consent from
each subject’s guardian(s) and assent from subjects seven years and older and took
measurements on day 5-7 of hospitalization and about six weeks after hospitalization.
Participants were compensated $5.00 at the initial appointment and $10.00 at the follow-up
appointment. The Intermountain Healthcare and Brigham Young University Institutional Review
Boards (IRB) approved the study.
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Data Collection
Prior to data collection, members of the research team were trained on proper sanitation
practices, how to use the Jamar® Plus Hand Dynamometer, and how to take anthropometric
measurements using National Health and Nutrition Examination Survey (NHANES) protocol.21
All measurements were taken by a single member of the research team or by trained outpatient
CF clinic staff. Weight during hospitalization was measured by the researcher using a mobile
mechanical scale (Seca 882) and before/after hospitalization by clinic staff using a stationary
mechanical scale (Scale-Tronix 5002) in the outpatient CF clinic; both were recorded to the
nearest 0.1 kg. Height was measured by clinic staff for all three time periods using a wallmounted stadiometer and was recorded to the nearest 0.1 cm. HGS was measured by gripping the
Jamar® Plus Hand Dynamometer with the subject in a seated position, maintaining an
unsupported elbow at the side of their body with the forearm stretched to a 90° angle. MUAC
was measured with a flexible, non-stretchable tape on the right arm halfway between the
acromion process of the scapula and olecranon process at the tip of the elbow following
NHANES procedures to the nearest 0.1 cm.21 Measurement of TSF also followed NHANES
procedures and were taken using a skinfold caliper to the nearest 0.1 mm.21 MUAC and TSF
measurements were used to calculate AMA z-scores.
Researchers examined data from three different periods: approximately five months
before hospitalization, day 5-7 of hospitalization, and approximately six weeks after
hospitalization at an outpatient CF clinic follow-up appointment. Weight, height, pulmonary
function (FEV1), and nutrition risk score were obtained from electronic medical records for all
three time periods (See Figure 1). Respiratory therapists measured pulmonary function as forced
5

expiratory volume at 1 second (FEV1). Nutrition risk scores were calculated by the registered
dietitian nutritionist (RDN) based on BMI percentile, daily weight gain, and annual height gain;
children with a score of 0-1 were no-low risk, 2-3 were moderate risk, and 4+ were high risk.5
The researcher measured HGS, TSF, and MUAC during hospitalization and at follow-up (See
Figure 1). Additionally, during hospitalization, the researcher reviewed a 3-day calorie count
conducted by the RDN to assess nutrient intake. Mean energy and protein intakes were
calculated in order to find what percentage of the child’s CF specific recommended energy and
protein needs were consumed. The researcher also recorded if the child was receiving nutrition
support and if the child had CF related diabetes (CFRD).
Statistical Analysis
Descriptive statistics including means and standard deviations were used to describe
patient demographics. HGS values were reported as z-scores based on means and standard
deviations published by and specific to the Jamar® Plus Hand Dynamometer.22 Dominant HGS
z-scores were assessed in all analyses. Differences between the three periods for BMI z-scores,
nutrition risk scores, and FEV1 were examined using a mixed models analysis. A similar mixed
models analysis was used to determine if HGS z-scores, BMI z-scores, and FEV1 differed
between hospitalization and follow-up. Regression analysis and analysis of variance (ANOVA)
were used to determine if there was a relationship among HGS z-score at hospitalization and the
following variables: BMI z-score, nutrition risk score, FEV1, MUAC z-score, TSF z-score, AMA
z-score, percent energy intake, and percent protein intake. All analyses were done using the
Statistical Analysis Systems statistical software package, version 9.4 (SAS Institute, Inc, Cary,
NC). Results were considered significant when p<0.05.
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RESULTS
Demographics
A total of 23 children with CF enrolled in the study and 22 completed the follow-up
appointment. Participants were primarily female (66%) ranging from 6-18 years with a mean age
of 12.4 years ± 4.0 at hospitalization. Four participants had CFRD and eight participants were
receiving nutrition support. Other demographic information is summarized in Table 1.
Outcomes
FEV1 values were significantly lower during hospitalization compared to before and after
hospitalization (p=0.001). No significant difference was found in BMI z-scores between the three
periods. HGS z-scores significantly improved after hospitalization (p=0.007); mean HGS zscores at hospitalization were -1.95 ± 0.92 and at follow-up were -1.59 ± 1.06 (Table 2). Eightytwo percent of participants experienced gains in HGS at their follow-up appointment. HGS zscores at hospitalization were not significantly related to BMI z-scores, FEV1, nutrition risk
scores, MUAC z-scores, TSF z-scores, or AMA z-scores at hospitalization. No significant
correlations were found between HGS z-scores and percent energy intake (p=0.913) or percent
protein intake (p=0.489).
DISCUSSION
This study used sex and age-adjusted HGS z-scores to indirectly measure LBM, which
has a stronger association with pulmonary function than BMI. 9, 10 Mean HGS z-scores of persons
with CF at hospitalization were very low compared to the standard (-1.95 ± 0.92), whereas mean
BMI z-scores at hospitalization were much closer to the standard (-0.09 ± 0.64) with 91% of
participants being classified as normal nutrition status.19 Mean BMI z-scores from this study
were very similar to those observed in another study of 75 children with CF (-0.09 ± 0.95).23 Our
7

study suggested participants may have deficits in LBM that were not detected by assessing BMI
alone. It is possible for children with CF to have reduced LBM and be classified as normal
nutrition status based on BMI. A study of 77 children with CF found LBM depletion
undetectable when using BMI percentile as the screening method.9 Additionally, LBM values
were found to be decreased in children with CF compared to healthy children with the same
BMI.10 BMI also failed to identify poor nutrition status in stunted children with CF.24 HGS may
be useful in identifying LBM depletion that is not apparent with BMI.
This study also found a significant change in HGS z-scores occurred from hospitalization
to follow-up (p=0.007). Eighty-two percent of individuals experienced increases in HGS at
follow-up. BMI z-scores, however, did not significantly change between hospitalization and
follow-up (p=0.178). HGS measures muscle function and has been shown to detect changes in
muscle mass sooner than BMI and other anthropometric measures in children >6 years.25, 26
Measuring muscle function allows for a more dynamic indicator of muscle mass compared to
BMI which takes longer to change.20 Additionally, the correlation between HGS and LBM is
stronger than the correlation between BMI and LBM in children ages 6-18 years.27 These
previous findings serve as a potential explanation for the observed change in HGS and lack of
change in BMI.
Researchers also wanted to identify whether or not meeting recommended energy and
protein needs would impact HGS z-scores. The majority of participants met their recommended
energy needs (74%) and their recommended protein needs (89%) based on a 3-day calorie count
during hospitalization. Little variation in regards to nutrient intake was present, and no
significant correlations with HGS z-scores were found. Thirty-five percent of participants were
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receiving nutrition support through enteral tube feedings; those receiving nutrition support had
significantly lower HGS z-scores (p=0.02).
This study included several limitations. The most notable being the small sample size.
Participants were recruited from one CF clinic that serves approximately 280 pediatric patients
ranging from infants to 18 years.28 To be included in the study, participants had to be between
ages 6-18 years and hospitalized following their outpatient CF clinic appointment. These two
factors alone did not allow for a large number of potential participants. Portions of our statistical
analyses were under powered, making it difficult to detect statistical significance. This may have
contributed to the lack of significant correlations found among HGS z-scores, nutrition status
(BMI z-scores, nutrition risk scores, and AMA z-scores), and pulmonary function (FEV1) at
hospitalization. Nevertheless, all statistical and meaningful findings were reported.
Additional limitations of the study included incomplete data for some participants. Four
participants were missing energy and protein intake values at hospitalization and three
participants were missing FEV1 values at follow-up. These participants were excluded from
analysis that incorporated their missing data. In an effort to obtain a reasonable sample size,
participants receiving nutrition support and those with CFRD were included. These conditions
have been shown to influence nutrition status and pulmonary function.2, 29, 30, 31 Although no
significant difference in HGS z-scores was observed in those with CFRD, those on nutrition
support did have significantly lower HGS z-scores. Females tend to have lower HGS compared
to males of the same age; the high percentage (66%) of female participants may have influenced
the results. 22, 32, 33 However, sex and age-adjusted HGS z-scores were used.
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CONCLUSION
In conclusion, HGS z-scores at hospitalization were much lower than the standard even
though mean BMI z-scores classified participants as normal nutrition status. HGS z-scores and
FEV1 significantly increased at follow-up; however, no significant relationship among HGS,
nutrition status (BMI z-scores, nutrition risk scores, and AMA z-scores), and pulmonary function
(FEV1) was found. Further research should be done utilizing a larger sample size of children with
CF in order to better examine HGS’s potential as a nutrition assessment tool in this population.
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Figure 1: Data Collection Timeline. BMI = body mass index, FEV1 = forced expiratory volume at 1
second, HGS = handgrip strength, MUAC = mid-upper arm circumference, TSF = triceps skinfolds,
AMA = arm muscle area
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TABLES
Table 1: Demographics of Participants

Total
participants
Gender
Male
Female
Age
6 – 11 years
12 – 18 years
Nutrition
Support
Yes
No
CF Related
Diabetes
Yes
No

Approximately 5
Months Before
Hospitalization
n
%
23
100

Day 5-7 of
Hospitalization
n
23

%
100

Approximately 6
Weeks After
Hospitalization
n
%
22
95.7

8
15

34.8
65.2

8
15

34.8
65.2

7
15

31.8
68.2

12
11

52.2
47.8

11
12

47.8
52.2

10
12

45.5
54.5

8
15

34.8
65.2

8
15

34.8
65.2

8
15

34.8
65.2

4
19

17.4
82.6

4
19

17.4
82.6

4
19

17.4
82.6
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Table 2: Clinical Characteristics of Participants
Approximately 5
Months Before
Hospitalization
Mean ± SD (n)
n/a

Day 5-7 of
Hospitalization
Mean ± SD (n)
-1.95 ± 0.92 (23)

Approximately 6
Weeks After
Hospitalization
Mean ± SD (n)
-1.59 ± 1.06 (22)

p value
0.007*

MUAC zscore
TSF z-score

n/a

-0.28 ± 0.81 (23)

-0.12 ± 0.66 (22)

0.361

n/a

-0.04 ± 0.76 (23)

0.03 ± 0.73 (22)

0.117

AMA zscore
BMI z-score

n/a

-0.30 ± 0.92 (23)

-0.22 ± 0.71 (22)

0.966

-0.17 ± 0.63 (23)a

-0.09 ± 0.64 (23)a

0.06 ± 0.54 (22)a

0.065

Nutrition
Risk Score
FEV1

1.52 ± 1.06 (23) a

1.57 ± 1.01 (23) a

0.91 ± 1.10 (22)b

0.049*

93.52 ± 17.35
(23)a

85.65 ± 21.57 (23)b

95.63 ± 18.18 (19)a

0.001*

Dominant
HGS z-score

HGS z-score = handgrip strength; MUAC z-score = mid-upper arm circumference; TSF z-score = triceps
skinfolds; AMA z-score = arm muscle area;
BMI z-score = body mass index: normal nutrition status= >-1, mild malnutrition= -1 to -1.9, moderate
malnutrition= -2 to -2.9, severe malnutrition= -3 or less;
Nutrition risk score: 0-1 = no-low nutrition risk, 2-3 = moderate nutrition risk, 4+ = high nutrition risk;
FEV1 = forced expiratory volume at 1 second, percentage predicted
*p<0.05
a
No significant difference
b
Significant difference
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APPENDIX A: RESEARCH PROPOSAL
Problem Statement
Cystic Fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene.1 The CFTR gene codes for CFTR
proteins that reside on the epithelial cells lining the lungs, digestive system, and sweat glands
and are responsible for regulating the flow of salts and fluids.1 CF symptoms occur because the
CFTR proteins are altered and cannot channel chloride ions as effectively or at all, resulting in
the production of mucus in the lungs, destruction of the pancreas in some individuals, and
difficulties with other organs.2 CF has significant pulmonary and nutrition components; in fact,
there is a longitudinal relationship between nutrition status, growth, pulmonary function, and
survival.3, 4, 5 Optimization of both nutrition status and growth are critical for effective treatment.3
CF Clinical Care Guidelines recommend maintaining a BMI above the 50th percentile or
a BMI z-score above zero for children and a BMI greater than 22-23 in adults.6 However, BMI is
not the best scale for measuring change in nutrition status.7 BMI is a measure of weight adjusted
for height and is incapable of distinguishing between lean body mass (LBM) and fat mass. In
individuals with CF a stronger association has been found between LBM and pulmonary
function than between BMI and pulmonary function.8 A depletion of LBM has been associated
with increased morbidity and was undetectable using BMI criterion in 48% of patients with CF.9
Dual-energy X-ray absorptiometry (DXA) scans are often used in research to measure variations
in body composition; however, they are expensive and impractical for everyday use in a clinic.
Bioelectrical impedance is another method to assess LBM but has been found to be inaccurate in
persons with CF due to an imbalance in electrolytes.10, 11 Arm anthropometric measurements
including triceps skinfolds (TSF), mid-upper arm circumference (MUAC), and arm muscle area
17

(AMA) have been reviewed as possible methods to assess LBM, yet these methods have led to
inconsistent results in the CF population.11, 12 It has been concluded that neither skinfold
measurements nor bioelectrical impedance should be included in the standard nutrition
assessment of CF patients.13
LBM is strongly associated with pulmonary function and is not detectable using BMI,
which means that a simple non-invasive method to examine LBM is needed. Handgrip strength
(HGS) measures muscle strength and is reflective of LBM.14 In fact, the correlation between
HGS and LBM in children is stronger than the correlation between LBM and BMI.15 In a crosssectional study of 25 adults with CF, HGS was reduced in the low LBM group.14 HGS may serve
as a valuable measurement in the CF population based on its association with LBM and potential
for earlier detection of muscle depletion. If HGS in children with CF is able to detect changes
overtime, it may serve as a more sensitive method for nutrition status assessment and
incorporating it routinely may result in improved nutrition status, pulmonary function, and
survival.16, 17
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Purpose Statements
The primary purposes of this research were to:
1) Assess if there was a relationship among HGS z-scores, nutrition status (BMI zscores, nutrition risk scores, and AMA z-scores), and pulmonary function (FEV1) in
children ages 6-18 years with CF
2) Assess if HGS z-scores changed between hospitalization and after hospitalization at
an outpatient CF clinic follow-up appointment

The secondary purpose of this research was:
1) Assess if there was a relationship between HGS z-scores and nutrient intake,
specifically energy and protein intake
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APPENDIX B: LITERATURE REVIEW
Cystic Fibrosis
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR) gene.1 The CFTR gene codes for CFTR
proteins that are responsible for regulating the flow of fluids and salts in and out of cells
throughout the body, specifically in the lungs, digestive tract, and sweat glands.1 CF symptoms
occur because CFTR proteins are altered and their ability to transport chloride is impaired. There
are over 1,800 possible mutations in the CFTR gene that result in CF. Location of the CFTR
proteins and type of mutation(s) in the CFTR genes determine where symptoms occur.2 F508del
is the most common mutation occurring in >90% of CF patients and results in the deletion of the
codon corresponding to the amino acid phenylalanine at position 508 of the CFTR gene.18, 19 In
order to have CF, a child must receive a copy of the mutated CFTR gene from both parents.
Children that only receive one mutated CFTR gene from a single parent will not have CF but
will be carriers of the disease. According to the Cystic Fibrosis Foundation Registry Annual Data
Report for 2013, there were 28,103 individuals in the United States living with CF, and 373 of
those individuals on the registry resided in the state of Utah.17 Worldwide it has been estimated
that there are about 70,000 people with CF.1 Approximately 1,000 new cases are diagnosed in
the US each year, with more than 75% of diagnosis occurring by the age of two years old.1
In the lungs mucus clearance is an important defense mechanism against disease.20 The
ability to clear airways through mucociliary clearance strongly depends upon the volume of
airway surface liquid (ASL), which consists of a mucus component that traps foreign particles
and a periciliary layer (PCL) that maintains optimum mucus distance from the cilia.21, 22 In those
with CF, reduced chloride secretion and increased sodium reabsorption in airway epithelium
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leads to reduced water content and reduced volume of PCL, which both contribute to inhibited
mucociliary clearance from the airways and to persistent infection.23, 24 Lung damage may occur
each time someone with CF develops a pulmonary infection, so infection control is critical.
Multiple precautions must be taken in order to prevent potential infection, including but not
limited to prevention of patient-to-patient contact and patient-to-health care worker contact,
appropriate hand hygiene for all those around, and sterilization of surroundings, specifically
respiratory therapy equipment.25 Infection control is an essential element of keeping the lungs of
CF patients healthy.
Along with the pulmonary component, 85-90% of individuals with CF suffer from
pancreatic insufficiency.26 The pancreas makes and secretes bicarbonate into the small intestine
to neutralize acidic content coming from the stomach. The pancreas also secretes pancreatic
enzymes that work to further breakdown carbohydrates, proteins, and fats from foods for
absorption. Bicarbonate allows pancreatic enzymes to work more efficiently. Failure of chloride
secretion results in mucus build up, which causes duct blockage and prevents bicarbonate and
pancreatic enzymes from entering the small intestine and may lead to pancreatitis.27 Pancreatic
insufficiency leads to malabsorption of dietary fat, protein, and other nutrients and has a direct
influence on nutrition status.28 Pancreatic insufficiency is most often treated by oral replacement
therapy of pancreatic enzymes to be taken with meals.19 Even with the addition of pancreatic
enzymes, in some cases fat malabsorption, fat-soluble vitamin deficiency, and steatorrhea
continue to occur.29
Impaired uptake of fat in the presence of pancreatic enzymes may be a result of
compromised bile composition and production in the liver.29 The bile produced in the liver may
become dehydrated and more acidic than regular bile. This change in bile can result in gallstones
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or total blockage of the liver ducts, which will ultimately influence the body’s ability to absorb
fat within the small intestine.
As patients age, pancreatic islets containing beta cells that secrete insulin may become
damaged resulting in the development of CF-related diabetes (CFRD).27 In CFRD the pancreas
either does not produce enough insulin or the insulin that it does produce does not work properly.
Individuals with CF ages ten and older should be tested every year for CFRD with an oral
glucose tolerance test.17 In CF, even if blood glucose levels are fairly normal, insulin deficiency
can lead to protein breakdown and malnutrition, which negatively impacts lung function and
potentially survival.17, 30, 31 CFRD is manageable with the addition of insulin, so early detection
is critical in order to maintain the upmost nutrition status.
CF can also affect other organs such as the kidneys, skin, and reproductive system. The
major CF symptoms include salty skin, continuous lung infections, decline in pulmonary
function, malabsorption, and poor weight gain and growth. At the present time, there is not a
cure for CF; however, scientists have and are continuing to develop treatments and therapies that
may be used to ease symptoms and prolong life. Numerous drugs with different aims such as
CFTR modulation, restoring airway surface liquid, mucus alteration, anti-inflammatories, antiinfections, and improved nutrition status are available and contributing to increased lifespan in
those with CF.32
Screening and Assessment of Children with CF
Early detection and diagnosis of CF plays an important role in improving nutrition status,
pulmonary function, and survival.14, 17 Newborn screening allows for earlier detection and
intervention, which has been shown to improve outcomes.16 Routine newborn screening is fairly
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new in the U.S.; as of 2010 all 50 states screen newborns for CF. One study compared health
statistics of children aged ≤ 18 years between the U.S. and Australia using the 2003 national data
registries for CF.33 Australia adopted newborn screening much earlier than the U.S., so there was
a significant difference in the proportion of individuals diagnosed by newborn screening between
the countries: U.S. (7.2%) and Australia (65.8%).33 The researchers found that Australian
children had significantly greater mean height and weight percentiles compared to American
children, and that children in both countries diagnosed with CF using newborn screening had
improved lung function.33 Multiple other studies suggest that a delay in diagnosis is associated
with worsened disease outcomes such as severe malnutrition and pulmonary infection.34, 35, 36
Overall earlier detection allows for earlier intervention, which ultimately is associated with
improved nutrition status, pulmonary function, and survival. 16, 17, 34
Once an individual is screened and diagnosed with CF, routine assessment is key in
maintaining optimal health. It is recommended by the CF Foundation Care Guidelines that
people with CF have four or more clinic visits each year.17 The CF Foundation Care Guidelines
also recommend four or more sputum/throat cultures per year, two or more lung function tests
(PFTs) per year, a measurement of fat-soluble vitamins once per year, an oral glucose tolerance
test if above ten years of age once per year, and a blood test to measure liver enzymes once per
year.17 These many tests are not completed at every single clinic appointment. However, at each
clinic appointment a nutrition screening process should be in place to identify CF patients with
poor nutrition status. A critical goal of the CF Foundation Care Guidelines is that children, teens
and adults with CF have normal growth and normal nutrition status.17 Poor nutrition status is
associated with reduced pulmonary function measured by forced expiratory volume at 1 second
(FEV1).
23

BMI is the primary accepted method to determine nutrition status in children with CF.6, 37
Research has shown that normal weight-for-age, normal weight-for-height, and normal heightfor-age percentiles and a BMI greater than the 50th percentile for ages 2-20 years are all
associated with better pulmonary function.3, 38 These anthropometric measurements are often
considered when assessing nutrition status in individuals with CF. Primary Children’s Hospital
in Salt Lake City, Utah uses a CF nutrition risk screening tool based on BMI percentile, daily
weight gain, and annual height that assigns each patient to a nutrition risk score category of nolow risk, moderate risk, or high risk. 38
Although there is a relationship between BMI and pulmonary function, an even stronger
relationship has been found between LBM and pulmonary in CF patients with pancreatic
insufficiency.8 It has been found that LBM is an important element of diaphragm strength and
longitudinal peak aerobic performance for children and adolescents with CF.39, 40 BMI is
incapable of distinguishing between LBM and fat mass and may not be the best scale for
measuring nutrition status changes in children.7 A depletion of LBM has been associated with
increased morbidity and found undetectable using BMI criterion in 48% of adults with CF.9 BMI
has also failed to identify poor nutrition status in stunted children with CF.41 Dual-energy X-ray
absorptiometry (DXA) scans are often used in research to measure variations in body
composition; however, they are expensive and impractical for everyday use in a clinic.
Bioelectrical impedance is another method to assess LBM but has been found to be inaccurate in
persons with CF due to imbalances in electrolytes.10, 11 Arm anthropometric measurements
including triceps skinfolds (TSF), mid-upper arm circumference (MUAC), and arm muscle area
(AMA) have been reviewed as possible methods to assess LBM, yet these methods have led to
inconsistent results in the CF population.11, 12 It has been concluded that neither skinfold
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measurements nor bioelectrical impedance should be included in the standard nutrition
assessment of CF patients.13 LBM is strongly associated with pulmonary function and is not
detectable using BMI, which means that a simple non-invasive method to measure LBM is
needed.
Overall improving nutrition status in children with CF is critical, yet challenging because
of difficultly absorbing nutrients as well as increased resting energy expenditure and reduced
appetite.42 The CF Foundation recommends energy intakes greater than the standard population
to breathe normally, fight infection, compensate for poor digestion, and to support an ageappropriate weight.3, 43 Improved weight status in both children and adults has been found at
energy intakes of 110% to 200% of energy needs for the healthy population of similar age, sex,
and size.3 Historically, nutrition therapy for individuals with CF has focused on increased fat
intake due to the malabsorption of fat. Yet, LBM is associated with pulmonary function and
survival, and optimal protein intake is important to prevent muscle loss. The median survival age
for CF has increased to 40 years, and there is more of a concern with sarcopenic obesity and
cardiovascular risk. For patients with a BMI > 25, there was significantly less improvement in
FEV1 with increased BMI compared to patients in the normal weight range.44 Increases in BMI
may be due to increases in fat mass or to increases in LBM; BMI is incapable of deciphering
between the two. This incapability illustrates the importance of a tool that is able to examine
LBM in children with CF in clinical settings.
Handgrip Strength
Handgrip strength measures muscle function and has been shown to detect changes in
muscle mass sooner than BMI and other anthropometric measures in children >6 years.45, 46 It is
a simple, non-invasive tool that is suitable for a clinical setting. HGS has been used to measure
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muscle function in a variety of populations, including adults with CF. 14, 47, 48 It has been found
that the correlation between HGS and LBM in children is stronger than the correlation between
LBM and BMI.15, 49 In a cross-sectional study of 25 adults with CF, handgrip strength and
pulmonary function was reduced in the low LBM.14 HGS is measured using handgrip
dynamometry. The Jamar® Hand Dynamometer is widely used to measure HGS due to its
established test-retest, inter-rater, and intra-rate reliability.50 Children with CF have reduced
muscle force, even in the absence of weakened nutrition status, which means that in order to
utilize HGS as a nutrition assessment tool, it must first must be studied specifically in children
with CF.51 Multiple studies have shown HGS to be a good indicator of increased postoperative
complications, increased length of hospitalization, increased rate of re-hospitalization, and
decreased physical status in adults.49 Silvia et al. looked at the relationship of HGS as an
indicator of nutrition status in hospitalized pediatric patients and found that HGS was associated
with undernutrition and that HGS decreased during hospital stay in 64% of the children.52
Minimal research has been done on HGS in children with CF, and no research to our knowledge
has been done comparing HGS in children with CF between hospitalization and after
hospitalization at a 6-week follow up appointment. Investigating the relationship between HGS
during hospitalization and after hospitalization could potentially provide evidence as to whether
HGS is capable of detecting changes over time. HGS may serve as a valuable measurement in
the CF population based on its ability to detect muscle depletion, accelerating the need for
nutrition intervention to reverse muscle loss and pulmonary function decline. As noted
previously, earlier detection of nutrition status decline is associated with improved nutrition
status, pulmonary function, and survival.16, 17
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APPENDIX C: COMPLETE METHODS
Study Setting and Design
A convenience sample of 23 children, ages 6-18 years, with cystic fibrosis (CF)
participated in a longitudinal study from August 2016 to April 2017. Eligible participants were
admitted to 289-bed pediatric specialty hospital within three days of their outpatient CF clinic
appointment, able to read and understand verbal directions in English, and able to perform the
HGS measurement. Children positive for Burkholderia cepacia were excluded. Eligible
participants and/or their guardian(s) were given a flyer explaining the study within 24-72 hours
of hospitalization. If the guardian(s) and child were interested, the registered dietitian nutritionist
(RDN) set up an appointment for the family to meet with the researcher on day 5-7 of
hospitalization. At this appointment, the researcher obtained consent from each subject’s
guardian(s) and assent from subjects seven years and older and took the appropriate
measurements. Participants were compensated $5.00 at the initial appointment and $10.00 at the
follow-up appointment. The Intermountain Healthcare and Brigham Young University
Institutional Review Boards (IRB) approved the study.
Data Collection
Prior to data collection, members of the research team were trained on proper sanitation
practices, how to use the Jamar® Plus Hand Dynamometer, and how to take anthropometric
measurements using National Health and Nutrition Examination Survey (NHANES) protocol.53
All measurements were taken by a single member of the research team or by trained outpatient
CF clinic staff. Weight during hospitalization was measured by the researcher using a
mechanical scale (Seca 882) and before/after hospitalization by clinic staff using a stationary
mechanical scale (Scale-Tronix 5002) in the outpatient CF clinic; both were recorded to the
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nearest 0.1 kg. Height was measured by clinic staff for all three periods using a wall-mounted
stadiometer and was recorded to the nearest 0.1 cm. HGS was measured by gripping the Jamar®
Plus Hand Dynamometer with the subject in a seated position, maintaining an unsupported elbow
at the side of their body with the forearm stretched to a 90° angle. Each subject was asked to
squeeze the hand dynamometer three times in each hand, alternating hands between each
measurement. The mean measurement of all three trials on both the dominant and non-dominant
hand was recorded. Mid-upper arm circumference (MUAC) was measured with a flexible, nonstretchable tape on the right arm halfway between the acromion process of the scapula and
olecranon process at the tip of the elbow following NHANES procedures to the nearest 0.1 cm.53
Measurement of triceps skinfolds (TSF) also followed NHANES procedures and were taken
using a skinfold caliper to the nearest 0.1 mm.53 MUAC and TSF measurements were used to
calculate arm muscle area (AMA) z-scores. All equipment was disinfected using hospital grade
sanitation wipes before and after measurements were taken.
Researchers examined data from three different periods: approximately five months
before hospitalization, day 5-7 of hospitalization, and approximately six weeks after
hospitalization at an outpatient CF clinic follow-up appointment. Weight, height, pulmonary
function, and nutrition risk score were obtained from electronic medical records for all three
periods (See Figure 1). Respiratory therapists measured pulmonary function as forced expiratory
volume at 1 second (FEV1). Nutrition risk score was calculated by the RDN based on BMI
percentile, daily weight gain, and annual height gain; children with a score of 0-1 were no-low
risk, 2-3 were moderate risk, and 4+ were high risk.38 The researcher measured HGS, TSF, and
MUAC during hospitalization and at follow-up (See Figure 1). Additionally, during
hospitalization, the researcher reviewed a 3-day calorie count conducted by the RDN to assess
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nutrient intake. The researcher was specifically interested in the amount of energy and protein a
child consumed and if that child met their recommended energy and protein needs. Mean energy
and protein intakes were calculated in order to find what percentage of the child’s CF specific
recommended energy and protein needs were met. The researcher also recorded if the child was
receiving nutrition support and if the child had CF related diabetes (CFRD).
Statistical Analysis
Descriptive statistics including means and standard deviations were used to describe
patient demographics. HGS values were reported as z-scores based on means and standard
deviations published by and specific to the Jamar® Plus Hand Dynamometer.54 Differences
between the three periods for BMI z-scores, nutrition risk scores, and FEV1 were examined using
a mixed models analysis. A similar mixed models analysis was used to determine if HGS zscores, BMI z-scores, and FEV1 differed between hospitalization and follow-up. Regression
analysis and analysis of variance (ANOVA) were used determine if there was a relationship
among HGS z-score at hospitalization and the following variables: BMI z-score, nutrition risk
score, FEV1, MUAC z-score, TSF z-score, AMA z-score, percent energy intake, and percent
protein intake. All analyses were done using the Statistical Analysis Systems statistical software
package, version 9.4 (SAS Institute, Inc, Cary, NC). Results were considered significant when
p<0.05.
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APPENDIX F: RECRUITMENT FLYER

RESEARCH PARTICIPANTS NEEDED
PURPOSE: This study will assess if there is a difference in handgrip strength in children with
cystic fibrosis during hospitalization compared their routinely scheduled follow up appointment.

ABOUT: This study will take place from June 2016 until June 2017 OR
until enough children have participated in the study. Research data will be
collected during your current hospitalization and at your routinely
scheduled follow-up appointment. Data collection will only take 15
minutes.
ELIGIBILITY: Participants in this study must be between the ages of
6-18, have cystic fibrosis, be able to follow verbal and written directions
in English, and be able to perform the handgrip strength measurement.
Participants must have been admitted to Primary Children’s Hospital
after attending the Intermountain Cystic Fibrosis Center.
COMPENSATION: Participants will be given $15 for participation. $5
will be given to the participant at hospitalization and $10 will be given at
the follow-up appointment.

BENEFITS of RESEARCH: Data collected from this research study
will add to a better understanding of nutritional status in children with
cystic fibrosis.
If you and your child are interested in participating in this study, please let your Registered
Dietitian know and provide a specific time that both you and your child are available to meet
the researcher on days 5-7 of child’s hospital stay:
Researcher Availability for August 2016-December 2016

Monday
8:00 am – 7:00 pm
Tuesday
8:00 am – 7:00 pm
Wednesday
8:00 am – 7:00 pm
Thursday
8:00 am – 7:00 pm
Friday
8:00 am – 7:00 pm
Saturday
8:00 am – 7:00 pm
Please choose a specific time within this range to meet with the researcher.
If you have any questions or would like to participate, please contact one of the following individuals:
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APPENDIX G: PARENTAL CONSENT FORM

Parental Permission Form

What

Handgrip Strength in Children with Cystic Fibrosis

Where

Primary Children’s Hospital
Jennifer Derrick MS, RDN
100 Mario Capecchi Dr.
Salt Lake City, UT 84132

Who

Primary Investigator: Sarah Gunnell Bellini PhD, RDN, CD (801)-422-0015
Co-investigators:

Intermountain Cystic Fibrosis Center
Catherine McDonald PhD, RDN, CD
100 Mario Capecchi Dr.
Salt Lake City, UT 84132

Jennifer W. Derrick MS, RDN, CD (801) 662-5310
Amanda Nederostek MS, RDN, CD (801)662-5303
Robin Aufdenkampe MS, RDN, CD (801) 662-5313
Catherine McDonald PhD, RDN, CD (801) 662-5314
Julie Spelman MBA, RDN, CD (801) 662-1404
Fadi Asfour MD (801) 213-3599
Hannah Gibson (801)-422-0015

When

During your child’s hospital stay and at your child’s follow-up appointment.

Why

This study will assess if there is a difference in handgrip strength in children with
cystic fibrosis during hospitalization compared to a 6-week follow-up
appointment.

How

If you agree to have your child participate, we will do the study during your
child’s current hospital stay and at your child’s routinely scheduled follow-up
appointment. During hospital stay, the researcher will measure weight, mid-upper
arm circumference, triceps skinfolds, and handgrip strength. Weight will be
measure by having you step onto a scale. The researcher will also measure midupper arm circumference with a tape measure and triceps skinfolds using a
skinfold caliper. The researcher will then measure handgrip strength by asking
your child to squeeze a special tool with his/her hand. The researcher will record
the numbers of all measurements. At the routinely scheduled follow-up
appointment, a researcher will again measure mid-upper arm circumference and
triceps skinfolds. The researcher will also again ask you to squeeze the tool used
to measure handgrip strength. The researcher will record the measurements.
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Why is this study being done?
We are asking you to give permission for your child to take part in a research study to see if there
is a difference in handgrip strength in children with CF during hospitalization compared to a 6week follow-up appointment. Handgrip strength is a simple measurement that may be used to
assess nutritional status if a relationship is found in this study. There is little information about
using handgrip strength to measure nutritional status in children with cystic fibrosis.
Why are you asking my child to take part in the study?
We are asking for your child to take part in this study because the study focuses on the handgrip
strength of children with cystic fibrosis aged 6-18 years to measure nutrition health. Your child is
a patient at Primary Children’s Hospital and meets the study’s inclusion criteria. Approximately
30 people will take part in this study at Primary Children’s Hospital.
Please read this form and ask any questions you may have before giving permission for
your child to be in this research study.
Who can be in the study?
We want to enroll children who…
- are between 6-18 years of age
- have cystic fibrosis
- are admitted to Primary Children’s Hospital
- are able to understand verbal and written directions in English
- have the ability to perform handgrip strength measurements
Who cannot be in the study?
Your child cannot participate in this study if s/he…
- is not between the ages of 6-18 years of age
- is unable to squeeze the handgrip strength tool
- is unable to read or understand directions in English
- is not currently admitted to Primary Children’s Hospital
- is positive for Burkholderia cepacia
If you agree for your child to be in this study, it will take about 15 minutes to collect the
measurements that will be done today. The researcher will measure your child’s weight, midupper arm circumference, triceps skinfolds, and ask them to squeeze the handgrip strength tool.
The tool that your child will be squeezing is similar to the one pictured below. The second
measurements of mid-upper arm circumference, triceps skinfolds, and handgrip strength will be
collected at the follow-up appointment that you schedule and will also take about 15 minutes. A
researcher will only measure mid-upper arm circumference, triceps skinfolds, and handgrip
strength at the follow-up appointment. The tool used to measure handgrip strength is pictured
below.
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Do I have to give permission for my child to be in the study?
No, you do not have to give permission. Your decision for your child to take part in this study is
completely voluntary.
What if I decide not to give permission?
You can choose not to have your child take part in this study and nothing about your child’s care
will change.
Can I change my mind later?
Yes. If you decide to give permission for your child to join the study, you can change your mind
and decide to stop at any time.
How long will my child be in the study?
Your child will be in the study for approximately 15 minutes at Primary Children’s Hospital and
for approximately 15 minutes at their follow-up appointment in the Intermountain Cystic
Fibrosis Center.
What will happen if I decide to let my child take part?
If you agree for your child to be in this study, the researcher will measure your child’s weight
and handgrip strength during their hospital stay. It will take about 15 minutes. The researcher
will also be present at your child’s follow-up appointment to measure handgrip strength, which
will take about 15 minutes.
What are the risks to my child if s/he is the study?
There are minimal risks for participation in this study. However, some children may experience
anxiety and discomfort from having his/her measurements taken. Your child may also potentially
have pain associated with squeezing the handgrip strength tool. If your child does experience
either of these issues, counseling and medical attention will be provided.
Are there any benefits to my child if s/he takes part in the study?
This study may help your child in the future. We hope to learn more about nutritional status in
children with CF by doing this research study. There are no anticipated benefits now.
What happens if my child is injured because s/he was in the study?
If your child becomes injured while taking part in this study, Intermountain Healthcare can
provide medical treatment. We will bill you or your insurance company in the usual
way. Because this is a research study, some insurance plans may not pay for the treatment. If
you believe your child has been injured as a result of being in this study, please call the Principal
Investigator right away. You may also call the Office of Research at 1-800-321-2107.
Who do I ask if I have questions about the study or my child’s rights?
If you have questions about the study please do not hesitate to call either Sarah Bellini at (801)
422-0015, Jennifer Derrick at (801) 662-5310 or Katie McDonald at (801) 662-5314.
If you have questions regarding your child’s rights as a research subject or if problems arise
which you do not feel you can discuss with the Investigator, please contact Intermountain’s
Office of Research at 1-800-321-2107.
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What are the costs of taking part in the study?
There will be no cost for participation in this study.
Will my child be paid to take part in the study?
Each participant will be given $5 during hospitalization and $10 at follow-up for participation in
this study.
If my child takes part in this study, what health information about him/her will you use?
Below is the health information from your child’s medical records that will be used in the study:
• Nutritional risk score
• Pulmonary Function
• Height
• Weight
• BMI
• 3-day calorie count (energy and protein intake)
• CF related diabetes, yes or no
• Currently on nutrition support, yes or no
o If yes, how long
Below is the health information that the researcher will measure directly from your child:
•
•
•
•

Weight
Mid-upper arm circumference
Triceps skinfolds
Handgrip Strength

The above health information will come from the information given to the researchers and from
your child’s medical records at hospitals and clinics where they’ve been treated.
The researchers will need to share your child’s information with others. This information will
not identify your child.
Important: You need to know that laws protect your child’s health information when it is held by
hospitals and healthcare providers. But if your child’s health information goes to someone else,
your child’s health information may not be protected by those laws.
•

•
•

Your child’s health information may be viewed for the following purposes, and laws
protect the confidentiality of your health information when used by these groups for
these purposes: Intermountain’s IRB (Institutional Review Board) to oversee the
safety and ethics of the study
Intermountain employees to do their job (such as give treatment, for billing matters,
or to make sure the research is done correctly).
The Food and Drug Administration and others to comply with law.
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If you decide to allow your child to take part in this study and sign this form, you permit
researchers to use your child’s health information for this study. If you want your child to take
part in this study, please sign this form. If you don’t want your child to participate, please don’t
sign this form.
You can always ask to see your child’s medical information at any time; however, you will not
be able to see your child’s health information that is used in this study until the study is finished.
Your agreement —which is called an authorization—to share your child’s health information as
part of this study will end when the study ends.
Consent
I confirm that I have read and understand this consent and authorization document and have had
the opportunity to ask questions. I understand that my child’s participation is voluntary and that
I am free to withdraw my child at any time, without giving any reason, without my medical care
or legal rights being affected. I will be given a signed copy of the consent and authorization
form to keep.
I agree to allow my child to participate in this research study and permit you to use and
disclose health information about my child for this study, as you have explained in this
document.
_______________________
Child’s Name
(Please Note: Both parents must give their permission unless one parent is deceased,
unknown, incompetent, not reasonably available, or when only one parent has legal
responsibility for the care and custody of the child. If both parents are not able to sign,
please list the name of the parent and the reason why they are not able to sign in the
signature line.)
Parent/ Guardian
Name

Parent/ Guardian Signature

Title

___________________________________________
Name of Person Obtaining Authorization and Consent
______________________________________________
Signature of Person Obtaining Authorization and Consent
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___________
Date

Date

APPENDIX H: PARTICIPANT ASSENT FORM

Assent Form
What

Handgrip Strength in Children with Cystic Fibrosis

Where

Primary Children’s Hospital
Jennifer Derrick MS, RDN
CD
100 Mario Capecchi Dr.
Salt Lake City, UT 84132

Who

Intermountain Cystic Fibrosis Clinic
Catherine McDonald PhD, RDN,
100 Mario Capecchi Dr.
Salt Lake City, UT 84132

Primary Investigator: Sarah Gunnell Bellini PhD, RDN, CD (801) 422-0015
Co-investigators:

Jennifer W. Derrick MS, RDN, CD (801) 662-5310
Amanda Nederostek MS, RDN, CD (801)662-5303
Robin Aufdenkampe MS, RDN, CD (801) 662-5313
Catherine McDonald PhD, RDN, CD (801) 662-5314
Julie Spelman MBA, RDN, CD (801) 662-1404
Fadi Asfour MD (801) 213-3599
Hannah Gibson (801) 422-0015

When

During your hospital stay and at your follow-up appointment.

Why

This study will assess if there is a difference in handgrip strength in children with
cystic fibrosis during hospitalization compared to a 6-week follow-up
appointment.

How

This is a summary of what we will be doing, described on the next few pages.

If you agree to participate, we will do the study during your current hospital stay and at your
follow-up appointment. During hospital stay, the researcher will measure weight, mid-upper arm
circumference, triceps skinfolds, and handgrip strength. Weight will be measure by having you
step onto a scale. The researcher will also measure mid-upper arm circumference with a tape
measure and triceps skinfolds using a skinfold caliper. The researcher will then measure
handgrip strength by asking you to squeeze a special tool with your hand. The researcher will
record the numbers of all measurements. At the routinely scheduled follow-up appointment, a
researcher will again measure mid-upper arm circumference and triceps skinfolds. The
researcher will also again ask you to squeeze the tool used to measure handgrip strength. The
researcher will record the measurements.
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What is a research study?
A research study is a way to find out new information about something. You do not need to be in
a research study if you do not want to.
Why are you asking me to be in this research study?
We are asking you to take part in this research study because we want to learn more about using
handgrip strength to measure nutrition health in children with cystic fibrosis.
Do my parents/guardian know about this study?
Yes. We have explained the study to your parents/guardian, and they said that we could ask you
if you want to be in this research study. Please talk about this with your parents before you
decide if you want to be in the study.
We will also ask your parents to give their permission for you to take part in this study. But even
if your parents say “yes” you can still decide not to be in this study.
Do I have to be in the study?
No, you do not have to be in this study. Being in this study is your choice and no one will be
upset if you don’t want to be in the study.
What will happen if I decide I want to be in the study?
If you agree to be in this study a researcher will measure your weight, mid-upper arm
circumference, triceps skinfolds, and ask you to squeeze the handgrip strength tool. Then when
you return to the hospital for your follow up appointment (in approximately 6 weeks) the
researcher will again measure mid-upper arm circumference, triceps skinfolds, and ask you to
squeeze the handgrip strength tool.
Can I get hurt if I join the study?
It is not likely that you will be hurt if you join this study. You have to have your weight, midupper arm circumference, and triceps skinfolds measured, and then squeeze a tool to measure
how strong you are. The tool you squeeze is similar to the one pictured below.
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Could this research study help me?
This study may help you in the future. We hope to learn more about nutrition in people with CF
by doing this research study. There are no anticipated benefits now.
Can I stop being in the study if I change my mind later?
Yes. Being in this study is up to you and no one will be upset if you change your mind later and
want to stop.
Who will see the information you collect about me?
All of your records about this research study will be kept locked up so no one else can see them.
The files will be kept in a locked filing cabinet and in a locked office. Information kept in the
computer will be password protected.

What if I have questions?
You can ask Katie McDonald in person or by telephone at 801-662-5314 any questions that you
have about the study. If you have a question later that you didn’t think of now, you can call
Sarah Bellini at 801-422-0015.
You can take more time to think about being in the study. Please also talk with your parents or
guardian about it. If you want to be in this research study, please write your name on the
‘participant’ lines below.
•

Remember, you can change your mind and stop being part of this study at any time

•

You and your parents will be given a copy of this paper to keep

_______________________________________
Name of participant (Please Print)
_______________________________
Participant signature

__________________
Date
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APPENDIX I: RECRUITMENT INSTRUCTIONS FOR RDNS

Recruitment Instructions for RDNs
Handgrip strength in Children with Cystic Fibrosis
Step 1: Provide flyer to parents of children that are eligible for this study. If the parent is not
there when you assess the child, please leave a flyer with the nurse.
Step 2: If the parent and child express interest in the study, have the parent select a time from the
flyer availability to meet with the researcher. If none of the times on the flyer work for the
parent, obtain a time that does work for the parent.
Step 3: Notify Hannah Gibson by email. Include date and time for her to come meet with the
parent and child. Do not include any patient information.
Hannah Gibson’s email: hannah.gibson@byu.net
Step 4: Record appointment time, potential subject name, and room number on the provided
appointment form posted in the dietitian office.
The researcher will call once a week to check to see if she has any upcoming appointments.
Who can be in the study?
We want to enroll children who…
- are between 6-18 years of age
- have cystic fibrosis
- are admitted to Primary Children’s Hospital
- are able to understand verbal and written directions in English
- have the ability to perform handgrip strength measurements
Who cannot be in the study?
A child cannot participate in this study if s/he…
- is not between the ages of 6-18 years of age
- is unable to squeeze the handgrip strength tool
- is unable to read or understand directions in English
- is not currently admitted to Primary Children’s Hospital
- is positive for Burkholderia cepacia
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APPENDIX J: APPOINTMENT FORM

HGS in Children with Cystic Fibrosis Appointment Form
Potential Subject Name

Room Number
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Date of Appointment

Time of Appointment

APPENDIX K: RETROSPECTIVE DATA COLLECTION SHEET
Retrospective
Q1 Date of Retrospective Data Collection
Q2 Study ID Number
Q3 Birthdate
Q4 Gender
 Male (1)
 Female (2)
Q5 Nutrition Support
 No (1)
 Yes (2) ____________________
Q6 CF Related Diabetes
 No (1)
 Yes (2)
Q7 Height
Q8 Weight
Q9 Pulmonary Function (FEV1 % Predicted)
Q10 Nutrition Risk Score
 No-low Risk (0-1) (1) ____________________
 Moderate Risk (2-3) (2) ____________________
 High Risk (4+) (3) ____________________
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APPENDIX L: HOSPITALIZATION DATA COLLECTION SHEET

Hospitalization
Q1 Date of Data Collection
Q2 Study ID Number
Q3 Birthdate
Q4 Gender
 Male (1)
 Female (2)
Q5 Dominant Hand
 Right (1)
 Left (2)
 Both (3)
Q6 Right HGS
Q7 Left HGS
Q8 Weight
Q9 MUAC
Q10 Triceps Skinfolds
Q11 Nutrition Support
 No (1)
 Yes (2) ____________________
Q12 CF Related Diabetes
 No (1)
 Yes (2)
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Q13 Height
Q14 Pulmonary Function (FEV1 % Predicted)
Q15 Nutrition Risk Score
 No-low Risk (0-1) (1) ____________________
 Moderate Risk (2-3) (2) ____________________
 High Risk (4+) (3) ____________________
Q16 Estimated Energy Needs from RDN
Q17 Mean Energy Intake
Q18 Percent Energy Intake
Q19 Estimated Protein Needs from RDN
Q20 Mean Protein Intake
Q21 Percent Protein Intake
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APPENDIX M: FOLLOW-UP DATA COLLECTION SHEET
Follow-up
Q1 Date of Follow-up
Q2 Study ID Number
Q3 Birthdate
Q4 Gender
 Male (1)
 Female (2)
Q5 Cystic Fibrosis Related Diabetes
 No (1)
 Yes (2)
Q6 Nutrition Support
 No (1)
 Yes (2) ____________________
Q7 Right HGS
Q8 Left HGS
Q9 Height
Q10 Weight
Q11 MUAC
Q12 Triceps Skinfolds
Q13 Pulmonary Function (FEV1 % Predicted)
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Q14 Nutrition Risk Score
 No-low Risk (0-1) (1) ____________________
 Moderate Risk (2-3) (2) ____________________
 High Risk (4+) (3) ____________________
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APPENDIX N: CF FOUNDATION GRANT APPLICATION

BUDGET & JUSTIFICATION
Trainee’s Salary or Stipend

$ 1,200

Supplies (itemize by major category)

$0

Other Expenses (itemize)
Incentives

$ 300

Total

$ 1,500

(Direct Costs only. No Indirect Costs allowed.)

Justification of supplies or other expenses, if applicable: (Note: A maximum of $300 may be
requested for project- related research supplies and other expenses.)
Other expenses: Each subject will receive an incentive of $15 for participation in the study. The
$300 requested will cover 20 of the 30 total subjects. The incentive cost for the remaining 10
subjects will be covered by internal funds.
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PROJECT DESCRIPTION
Maximum: Three pages.
Provide a concise description of the proposed project. Briefly state the hypothesis to be studied,
its relationship to cystic fibrosis, methods to be used (experimental design), and expected
outcomes from the study.
Background and Hypothesis
Optimization of nutritional status and growth in the cystic fibrosis (CF) population is
associated with increased pulmonary function and is critical for effective treatment.1 Body mass
index (BMI) is currently the accepted method to determine nutritional status in children with
CF.2 BMI is a measure of weight adjusted for height (kg/m2) and is incapable of distinguishing
between lean body mass (LBM) and fat mass. In the past few years, newer research suggests a
stronger association between LBM and pulmonary function than BMI and pulmonary function in
CF patients.3, 4, 5 However, BMI is still being used to measure nutritional status in clinical
settings. DXA scans are commonly used in research to measure LBM; however, they are
expensive and impractical for everyday use in a clinic. Bioelectrical impedance and triceps
skinfolds have been assessed as possible methods to indirectly measure LBM in some
populations, yet these methods have led to inconsistent results.6 Handgrip strength (HGS) is a
validated tool that has been used to measure muscle strength in a variety of populations.7, 8, 9
Research has shown that muscle strength is reflective of LBM and that muscle function responds
earlier to changes in nutritional status.10 More specifically, positive associations have been found
between HGS and LBM in adults with CF, and positive associations have also been found
between low HGS and undernutrition in hospitalized pediatric patients at admittance.9, 11 To our
knowledge, HGS has not been measured overtime in children with CF. Due to the strong
associations between LBM and pulmonary function and between HGS and LBM, HGS serves as
a potentially crucial measurement in assessing nutritional status in children with CF.
The specific aim of this research project is to assess if there is a difference in HGS in
children with CF during hospitalization compared to HGS at a 6-week follow-up appointment.
Differences in HGS between hospitalization and follow-up would indicate changes in LBM.
LBM has been found to have a strong association with pulmonary function and is an important
element of diaphragm strength. 3, 4, 5, 12 Improving pulmonary function is key in CF treatment.
HGS may be a more sensitive way to measure changes in LBM overtime compared to the
traditional use of BMI. This study will examine the relationship among HGS, BMI, and
pulmonary function. This study will also assess the relationship among HGS, nutrient intake, and
nutrition status. Researchers are interested in nutrient intake in order to determine what
percentages of each child’s estimated energy/protein needs were consumed in a standardized 3day calorie count. Researchers want to determine if % energy intake and % protein intake are
associated with HGS. This information is important in understanding if there is a correlation
between what an individual is consuming and their HGS. The relationship between HGS and
nutrition status (determined by the nutrition risk score) is important to examine because nutrition
risk scores (NRS) are routinely calculated in the CF pediatric population. The score is based on
BMI percentile, daily weight gain, and annual height gain and is used to identify children that
may benefit from more extensive medical nutrition therapy. The significance of these findings
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are to determine whether or not HGS serves as a useful tool to measure nutritional status in
children with CF.
We hypothesize that:
1. HGS measurements taken at the 6-week follow-up appointment will differ from
measurements taken during hospitalization
2. HGS will be positively associated with BMI, pulmonary function, nutrient intake, and
nutrition status
Methods and Experimental Design
A longitudinal study design will be used to examine if there is a difference between HGS
in children with CF during hospitalization compared to HGS at a post-hospitalization 6-week
follow-up appointment. The study population will consist of approximately 30 children with CF
that are admitted to the Primary Children’s Hospital (PCH) after attending the Intermountain
Cystic Fibrosis Center (ICFC) in Salt Lake City, UT. Children with CF are commonly admitted
to the hospital after attending ICFC if they have reduced pulmonary function, a respiratory
infection, weight loss, or another complication. The inclusion criteria are: children aged 6-18
years with CF, must be admitted to PCH for 7-14 days after ICFC attendance, must have the
ability to perform handgrip strength test, and both parent and child must be able to understand
verbal and written directions in English. In an effort to maintain infection control, children with
Burkholderia cepacia will be excluded. The age range of 6-18 years has been chosen based on
the physical ability to have HGS measured and because the HGS tool to be used in the study
(Jamar® Plus Hand Dynamometer) has been validated for this range.13, 14
Subjects will be recruited during hospitalization within the inpatient wing of PCH.
Potential subjects will receive a flyer detailing the study within 24-72 hours of hospital
admittance from the registered dietitian nutritionist (RDN) conducting the routine initial nutrition
assessment. If the parent/guardian and child are interested, the RDN will set up an appointment
for the family to meet with the designated researcher on day 5-7 of hospitalization. At the
scheduled appointment, the researcher will explain the study in detail and answer any questions
the family may have. If the parent and child wish to participate in the study, the researcher will
obtain consent and/or assent and then proceed to taking the appropriate measurements.
On the day the child attended ICFC before hospital admittance, trained ICFC staff will
measure/calculate height (cm), pulmonary function (FEV1), and NRS (range). On day 5-7 of
hospitalization the researcher will measure weight (kg) and HGS. The participant’s weight will
be measured using a mechanical scale (Seca 882) and will be recorded to the nearest 0.1 kg.15
HGS will be recorded to the nearest 0.01.13, 14 The researcher will calculate BMI using the
weight obtained on day 5-7 and the height measured by ICFC trained staff on the day of hospital
admission. A standardized 3-day calorie count will be administered to each subject during
hospitalization as routine hospital protocol, and the researchers will use this information to
examine the relationship between % energy intake, % protein intake, and HGS.16 Approximately
6-weeks after hospitalization a routine follow-up appointment will be scheduled in the ICFC. At
the follow-up appointment the same researcher that took measurements on day 5-7 of
hospitalization will measure HGS. Also at the follow-up appointment, trained ICFC staff will
measure/calculate weight, height, pulmonary function, BMI, and NRS. Additionally, researchers
will examine the following retrospective data (approximately 6 months before hospitalization)
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from subjects’ medical records: weight, height, pulmonary function, BMI, and NRS. Medical
record access has been requested in the submitted IRB application.
Data Analysis Plan
Means, medians, and standard deviations will be calculated for all variables: HGS,
height, weight, BMI, pulmonary function, NRS, % energy intake, and % protein intake. Paired ttests will be used to compare means of HGS, BMI, and pulmonary function between
hospitalization and follow-up. An analysis of covariance and regression models will determine
relationships between the dependent variable HGS and the independent variables height, weight,
BMI, pulmonary function, NRS, % energy intake, and % protein intake. Relationships will be
analyzed for multiple points in time: 6 months before hospitalization, at hospitalization, and 6weeks post hospitalization. HGS data will only be available at hospitalization and at follow-up;
no retrospective data will be available for HGS. Categorical variables include pulmonary
function (FEV1), NRS, % energy intake, and % protein intake. FEV1 and NRS both have
reference ranges that will be used to place these variables into categories.16, 17, 18 Percent energy
intake and % protein intake represent the percentage of estimated energy/protein needs met and
will be separated into one of four categories: sufficient nourishment, mild malnutrition, moderate
malnutrition, or severe malnutrition.16 Continuous variables include HGS, BMI, height, and
weight. Gender and age will be controlled for in all models because of their influence on HGS.11
The significance level will be set at p<0.05.
Expected Outcomes
Researchers expect HGS measurements taken at the follow-up appointment to differ from
HGS measurements taken during hospitalization. Positive associations are anticipated to occur
between HGS and the following: BMI, pulmonary function, nutrition status, % energy intake,
and % protein intake. Identifying LBM changes in children with CF is critical for effective
treatment based on its positive association with pulmonary function.9 BMI is currently the
accepted method to determine nutritional status in children and is incapable of identifying
changes in LBM.2 HGS may serve as a potentially crucial measurement in the pediatric CF
population based on its ability to detect muscle depletion; this detection would accelerate the
need for nutrition intervention in order to reverse muscle loss and to prevent and/or improve
pulmonary function decline.
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